title: Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
authors.forename: Bruce
authors.initials: B
authors.lastname: Patsner
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards*; D018572:Disease-Free Survival; D023381:Endpoint Determination / Q000592:standards*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents